Related Experiment Video
Updated: May 11, 2026

Scanning Light Scattering Profiler (SLPS) Based Methodology to Quantitatively Evaluate Forward and Backward Light Scattering from Intraocular Lenses
Published on: June 6, 2017
Intraocular lens calculation for aspheric intraocular lenses
Peter C Hoffmann1, Christoph R Lindemann
1Augenklinik Castrop-Rauxel, Castrop-Rauxel, Germany. ph@augenklinik-castrop-rauxel.de
Purpose:
To evaluate the possible benefits of biometry and ray-tracing intraocular lens (IOL) calculation for aspheric aberration-correcting IOLs.
Setting:
Private eye clinic in Germany.
Design:
Retrospective consecutive case series.
Methods:
Eyes with 3 different aberration-correcting IOLs were reviewed. Before surgery, the axial length, corneal thickness, anterior chamber depth, crystalline lens thickness, and corneal radii were measured with the Lenstar biometer. Subjective refraction was taken 1 month after surgery. Okulix ray-tracing software (version 8.79) and the Hoffer Q, Holladay, and SRK/T formulas were used to calculate a prediction error based on preoperative biometry data, the given IOL, and the manifest refraction.
Results:
The study evaluated 308 eyes of 185 patients. The median absolute error was 0.28 diopters (D) for the Hoffer Q, 0.27 D for the Holladay, 0.28 D for the SRK/T, and 0.24 D for ray-tracing calculation. Using ray-tracing calculation, 95% of eyes were within ±0.71 D of the predicted refraction as opposed to ±0.85 D with the Hoffer Q, ±0.82 D with the Holladay, and ±0.84 D with the SRK/T.
Conclusions:
Ray tracing based on biometry data improved IOL prediction accuracy over conventional formulas in normal eyes implanted with aberration-correcting IOLs. The number of outliers can also be reduced significantly.
Financial Disclosure:
Neither author has a financial or proprietary interest in any material or method mentioned.
Related Concept Videos
Focusing of Light in the Eye
Glaucoma: Overview
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
